Evidence map›Paper›PMID 32117783›Full record

ArticleFrontiers in oncology2019

Comprehensive Molecular Profiling for Relapsed/Refractory Pediatric Burkitt Lymphomas-Retrospective Analysis of Three Real-Life Clinical Cases-Addressing Issues on Randomization and Customization at the Bedside.

Kristyna Polaskova, Tomas Merta, Alexandra Martincekova, Danica Zapletalova, Michal Kyr, Pavel Mazanek, Zdenka Krenova, Peter Mudry, Marta Jezova, Jiri Tuma and 16 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 6 institutions in 1 country.

Kristyna PolaskovaDepartment of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
Tomas MertaDepartment of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
Alexandra MartincekovaDepartment of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
Danica ZapletalovaDepartment of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
Michal KyrDepartment of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
Pavel MazanekDepartment of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
Zdenka KrenovaDepartment of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
Peter MudryDepartment of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
Marta JezovaDepartment of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
Jiri TumaDepartment of Pediatric Surgery, Orthopedics and Traumatology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
Jarmila SkotakovaDepartment of Pediatric Radiology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
Ivana CervinkovaDepartment of Pediatric Radiology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
Dalibor ValikDepartment of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czechia.
Lenka Zdrazilova-DubskaDepartment of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czechia.
Hana NoskovaCentral European Institute of Technology, Masaryk University, Brno, Czechia.
Karol PalCentral European Institute of Technology, Masaryk University, Brno, Czechia.
Ondrej SlabyCentral European Institute of Technology, Masaryk University, Brno, Czechia.
Pavel FabianDepartment of Oncological Pathology, Masaryk Memorial Cancer Institute, Brno, Czechia.
Sarka KozakovaInternational Clinical Research Center, St. Anne's University Hospital, Brno, Czechia.
Jakub NeradilInternational Clinical Research Center, St. Anne's University Hospital, Brno, Czechia.
Renata VeselskaInternational Clinical Research Center, St. Anne's University Hospital, Brno, Czechia.
Veronika KanderovaChildhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University, Prague, Czechia.
Ondrej HrusakChildhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, 2nd Faculty of Medicine, Charles University, Prague, Czechia.
Tomas FreibergerCentral European Institute of Technology, Masaryk University, Brno, Czechia.
Giannoula Lakka KlementDepartment of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
Jaroslav SterbaDepartment of Pediatric Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia.
Masaryk University · CZUniversity Hospital Brno · CZCentral European Institute of Technology – Masaryk University · CZMasaryk Memorial Cancer Institute · CZSt. Anne's University Hospital Brno · CZCharles University · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In order to identify reasons for treatment failures when using targeted therapies, we have analyzed the comprehensive molecular profiles of three relapsed, poor-prognosis Burkitt lymphoma cases. All three cases had resembling clinical presentation and histology and all three patients relapsed, but their outcomes differed significantly. The samples of their tumor tissue were analyzed using whole-exome sequencing, gene expression profiling, phosphoproteomic assays, and single-cell phosphoflow cytometry. These results explain different treatment responses of the three histologically identical but molecularly different tumors. Our findings support a personalized approach for patient with high risk, refractory, and rare diseases and may contribute to personalized and customized treatment efforts for patients with limited treatment options like relapsed/refractory Burkitt lymphoma. SUMMARY: The main aim of this study is to analyze three relapsed Burkitt lymphoma patients using a comprehensive molecular profiling, in order to explain their different outcomes and to propose a biomarker-based targeted treatment. In cases 1 and 3, the tumor tissue and the host were analyzed prospectively and appropriate target for the treatment was successfully implemented; however, in case 2, analyses become available only retrospectively and his empirically based rescue treatment did not hit the right target of his disease.

Indexed as

Burkitt lymphomapediatric oncologyprecision medicinetargeted therapytheranostics

Identifiers

PMID32117783
PMCPMC7027364
OpenAlexW3005349882

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.